Walleye Capital LLC purchased a new position in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 182,939 shares of the biotechnology company's stock, valued at approximately $1,003,000. Walleye Capital LLC owned approximately 0.85% of Agenus at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company's stock worth $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company's stock worth $208,000 after purchasing an additional 123,058 shares during the last quarter. Federated Hermes Inc. acquired a new position in Agenus in the second quarter worth $1,921,000. Susquehanna Fundamental Investments LLC bought a new stake in Agenus during the second quarter valued at $1,050,000. Finally, Ovata Capital Management Ltd acquired a new stake in shares of Agenus during the second quarter worth $670,000. Institutional investors own 61.46% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on AGEN shares. B. Riley lowered their price objective on shares of Agenus from $42.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a "neutral" rating on shares of Agenus in a report on Thursday. Finally, StockNews.com downgraded Agenus from a "hold" rating to a "sell" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $10.00.
Get Our Latest Research Report on Agenus
Agenus Trading Up 14.0 %
Agenus stock traded up $0.44 during midday trading on Friday, reaching $3.58. 441,268 shares of the stock traded hands, compared to its average volume of 742,636. The firm has a fifty day moving average price of $3.98 and a two-hundred day moving average price of $7.83. Agenus Inc. has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The firm has a market cap of $83.98 million, a price-to-earnings ratio of -0.32 and a beta of 1.24.
Agenus Profile
(
Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
